Diana Bitner, MD, MSCP, FACOG
Articles
Final Thoughts on Vasomotor Symptoms and NK Receptor Antagonism
Panelists discuss how advancing NK receptor research is reshaping menopause care, emphasizing education, innovation, and patient empowerment for lasting impact.
Practical Strategies for Integrating NK Receptor Antagonism for Vasomotor Symptoms Into Primary Care
Panelists discuss how structured monitoring and interdisciplinary collaboration enable safe, effective integration of NK-targeted therapies into primary care.
Positioning NK Receptor Antagonism in the Vasomotor Symptoms Treatment Landscape
Panelists discuss how NK receptor antagonists can be strategically positioned as core nonhormonal options within the broader VMS treatment landscape.
Beyond Vasomotor Symptoms: The Potential Role of NK Receptor Antagonism in Mood and Sleep
Panelists discuss how NK receptor antagonism may improve mood and sleep quality, linking thermoregulation with broader emotional and cognitive health benefits.
Exploring the Broader Therapeutic Potential of NK1 Receptor Antagonists Beyond Vasomotor Symptoms
Panelists discuss how NK1 receptor antagonists show promise beyond VMS, suggesting wider therapeutic potential across neurological and systemic conditions.
Efficacy and Safety of Elinzanetant in Vasomotor Symptoms in Menopause
Panelists discuss how elinzanetant demonstrates strong efficacy and safety across trials, reinforcing neurokinin modulation as a viable core treatment for VMS.
Dual NK3/NK1 Receptor Antagonism for Vasomotor Symptoms
Panelists discuss how dual NK3/NK1 receptor antagonism may expand therapeutic benefits by targeting multiple neural pathways involved in VMS and mood regulation.
Managing Vasomotor Symptoms With NK3 Receptor Antagonism
Panelists discuss how NK3 receptor antagonism through fezolinetant offers effective, rapid relief from VMS with a strong safety profile and nonhormonal benefits.
NK Receptor Antagonism as Therapeutic Strategy for Vasomotor Symptoms
Panelists discuss how NK receptor antagonism provides a targeted, nonhormonal strategy that addresses the physiological root of vasomotor symptoms.
Unmet Needs in Managing Vasomotor Symptoms in Menopause
Panelists discuss how limited treatment options and systemic barriers underscore the urgent need for accessible, targeted therapies for vasomotor symptoms.
Impact of Vasomotor Symptoms on Patient Quality of Life
Panelists discuss how vasomotor symptoms undermine physical comfort, sleep, and long-term health, emphasizing integrative management to restore overall quality of life.
Pathophysiology of Vasomotor Symptoms in Menopause
Panelists discuss how hormonal decline and KNDy neuron overactivation drive vasomotor symptoms and inform the development of targeted neurokinin receptor therapies.
